Medtronic, Inc. Clinical Trial Evaluating the Industry’s First Cryoballoon Technology Designed for Paroxysmal Atrial Fibrillation Completes Follow Up

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced completion of a 12-month follow up in the STOP-AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial evaluating the first cryoballoon catheter technology designed to treat paroxysmal atrial fibrillation – the Medtronic Arctic Front® CryoAblation Catheter System. Atrial fibrillation (AF) is the most common arrhythmia affecting more than 3 million Americans and 7 million people worldwide.¹ After the study data are analyzed and filed with regulatory authorities, the results will be shared at an upcoming medical meeting. The system is approved for use in Europe, Australia and Hong Kong and is under investigational use in the United States.
MORE ON THIS TOPIC